EP1328508A2 - Propionsäurederivate mit ppar-alpha aktivierenden eigenschaften - Google Patents

Propionsäurederivate mit ppar-alpha aktivierenden eigenschaften

Info

Publication number
EP1328508A2
EP1328508A2 EP01974287A EP01974287A EP1328508A2 EP 1328508 A2 EP1328508 A2 EP 1328508A2 EP 01974287 A EP01974287 A EP 01974287A EP 01974287 A EP01974287 A EP 01974287A EP 1328508 A2 EP1328508 A2 EP 1328508A2
Authority
EP
European Patent Office
Prior art keywords
methyl
amino
phenyl
compounds
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01974287A
Other languages
German (de)
English (en)
French (fr)
Inventor
Klaus Urbahns
Michael Woltering
Susanne Nikolic
Josef Pernerstorfer
Berthold Hinzen
Elke Dittrich-Wengenroth
Hilmar Bischoff
Claudia Hirth-Dietrich
Klemens Lustig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10124905A external-priority patent/DE10124905A1/de
Application filed by Bayer AG filed Critical Bayer AG
Publication of EP1328508A2 publication Critical patent/EP1328508A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the present application relates to new, potent PPAR-alpha-activating Nerbin fertilizers for the treatment of, for example, coronary heart disease and its
  • CAD coronary artery disease
  • fibrates are the only therapeutic option for patients in these risk groups. They act as weak agonists of the peroxisome proliferator-activated receptor (PPAR) -alpha (Nature 1990, 347, 645-50). A disadvantage of previously approved fibrates is their weak interaction with the receptor, which leads to high daily doses and significant side effects.
  • PPAR peroxisome proliferator-activated receptor
  • WO 00/23407 describes PPAR modulators for the treatment of obesity, atherosclerosis and / or diabetes.
  • the object of the present invention was to provide new compounds which can be used as PPAR-alpha modulators.
  • A represents a bond or a -CH 2 - or -CH 2 CH 2 - group
  • X represents O, S or CH 2 ,
  • R 1 , R 2 and R 3 are the same or different and are independently hydrogen, (-CC 6 ) -alkyl, (C 3 -C 7 ) -cycloalkyl, hydroxy, (-CC 6 ) alkoxy, (C 6 -C ⁇ o) aryloxy, halogen, trifluoromethyl, trifluoromethoxy, (CrC 6 ) -
  • R 1 and R 2 are bonded to two adjacent carbon atoms and, together with them, form a fused cyclohexane or benzene ring, the latter optionally being substituted by a (C 1 -C 4 ) alkylsulfonylmethyl group,
  • R 4 represents hydrogen or (Ci -C 4 ) alkyl
  • R 5 and R 6 are hydrogen or together with the carbon atom to which they are attached form a carbonyl group
  • R 7 represents hydrogen, (dC 6 ) -alkyl, phenyl or benzyl, in which the aromatics mentioned may in turn in each case be substituted one to three times identically or differently by (-C ⁇ -alkyl, (dC ⁇ -alkoxy, hydroxy or halogen), stands,
  • R 8 represents hydrogen, (C 6 -C ⁇ o) aryl or (C -C 4 ) alkyl, which in turn by hydroxy, trifluoromethoxy, (-C ⁇ alkoxy or phenoxy, which in turn, if necessary, once or twice by trifluoromethyl are substituted, or can be substituted by (C 6 -C 10 ) aryl or 5- to 6-membered heteroaryl with up to three heteroatoms from the series N, O and or S, all of the aryl and heteroaryl rings mentioned in turn in each case one to three times, identical or different, can be substituted by halogen, hydroxy, (CC ⁇ alkyl, (-C ⁇ alkoxy, trifluoromethyl, trifluoromethoxy, cyano, nitro or amino),
  • R 9 and R 10 are the same or different and are independently hydrogen, (CC 6 ) alkyl, (C r C 6 ) alkoxy, trifluoromethyl, trifluoromethoxy or halogen,
  • R represents hydrogen or a hydrolyzable group which can be broken down into the corresponding carboxylic acid
  • Such groups are exemplary and preferably: benzyl, (dC 6 ) alkyl or (C 3 - C 8 ) cycloalkyl, each optionally one or more times, identically or differently, by halogen, hydroxyl, amino, (dC 6 ) - Alkoxy, carboxyl, (dC 6 ) -
  • Alkoxycarbonyl, (dC 6 ) -alkoxycarbonylamino or (dC 6 ) -alkanoyloxy are substituted, or in particular (dC) -alkyl, which may be substituted one or more times, identically or differently, by halogen, hydroxy, amino, (C ⁇ -Q) - Alkoxy, carboxyl, (dC) -alkoxycarbonyl, (dC ⁇ -alkoxycarbonylamino or (dC 4 ) - alkanoyloxy is substituted.
  • (-CC 6 ) -alkyl and (dC 4 ) -alkyl stand for a straight-chain or branched alkyl radical having 1 to 6 or 1 to 4 carbon atoms.
  • a straight-chain or branched alkyl radical having 1 to 4 carbon atoms is preferred. The following may be mentioned by way of example and preferably: methyl, ethyl, n-propyl,
  • (C 6 -do) aryl stands for an aromatic radical having 6 to 10 carbon atoms.
  • the aryl radical is phenyl, for example and preferably.
  • (C 3 -C 8 ) cycloalkyl and (C 4 -C 7 ) cycloalkyl stand for a cycloalkyl group with 3 to 8 or 4 to 7 carbon atoms. Examples and preferably mentioned are: cyclobutyl, cyclopentyl and cyclohexyl.
  • (dC ö ⁇ alkoxy in the context of the invention is a straight-chain or branched alkoxy radical having 1 to 6 carbon atoms.
  • a straight-chain is preferred or branched alkoxy radical having 1 to 4 carbon atoms.
  • the following may be mentioned as examples and preferably: methoxy, ethoxy, n-propoxy, isopropoxy, t-butoxy, n-pentoxy and n-hexoxy.
  • (C 6 -C 10 ) aryloxy represents an aromatic radical having 6 to 10 carbon atoms which is linked via an oxygen atom.
  • the aryloxy radical is phenoxy, for example and preferably.
  • (dC 6 ) -alkoxycarbonyl represents a straight-chain or branched alkoxy radical having 1 to 6 carbon atoms which is linked via a carbonyl group.
  • a straight-chain or branched alkoxycarbonyl radical having 1 to 4 carbon atoms is preferred. The following may be mentioned by way of example and preferably: methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl and t-butoxycarbonyl.
  • (-CC 6 ) -alkoxycarbonylamino in the context of the invention represents an amino group with a straight-chain or branched alkoxycarbonyl substituent which has 1 to 6 carbon atoms in the alkoxy radical and is linked via the carbonyl group.
  • An alkoxycarbonylamino radical having 1 to 4 carbon atoms is preferred. Examples and preferably mentioned are: methoxycarbonylamino,
  • (dC 6 ) -alkanoyloxy represents a straight-chain or branched alkyl radical having 1 to 6 carbon atoms, which carries a double-bonded oxygen atom in the 1 position and is linked via a further oxygen atom in the 1 position.
  • the following may be mentioned by way of example and preferably: acetoxy, propionoxy, n-butyroxy, i-butyroxy, pivaloyloxy, n-hexanoyloxy.
  • (dC ⁇ -Alkylaminosulfonyl stands in the context of the invention for an amino group which is linked via a sulfonyl group and which is a straight-chain or mixed has branched alkyl substituents having 1 to 6 carbon atoms.
  • An alkylaminosulfonyl radical having 1 to 4 carbon atoms is preferred. Examples and preferably mentioned are: methylaminosulfonyl, ethylaminosulfonyl, n-propylaminosulfonyl, isopropylaminosulfonyl and t-butylaminosulfonyl.
  • Halogen in the context of the invention represents fluorine, chlorine, bromine and iodine. Chlorine or fluorine are preferred.
  • 5- to 6-membered heteroaryl with up to 3 heteroatoms from the series S, N and / or O generally represents a monocyclic in the context of the invention
  • Heteroaromatic which is linked via a ring carbon atom of the heteroaromatic, optionally also via a ring nitrogen atom of the heteroaromatic.
  • Examples include and are preferably: furanyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl. Furanyl, thienyl and oxazolyl are preferred.
  • the Neritatien according to the invention can exist in stereoisomeric forms which either behave like image and mirror image (enantiomers) or which do not behave like image and mirror image (diastereomers).
  • the invention relates to both the enantiomers or
  • Diastereomers as well as their respective mixtures. Like the diastereomers, the racemic forms can be separated into the stereoisomerically uniform constituents in a known manner.
  • the Neritatien invention can also be present as salts.
  • Physiologically acceptable salts are preferred in the context of the invention.
  • Physiologically acceptable salts can be salts of the inventive compounds with inorganic or organic acids. Salts with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid are preferred, or salts with organic carboxylic or sulfonic acids such as acetic acid, propionic acid, maleic acid, fumaric acid, malic acid, citric acid, tartaric acid, lactic acid, benzoic acid or methanesulfonic acid , Ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid or ⁇ aphthalenedisulfonic acid.
  • Physiologically acceptable salts can also be salts of the invention
  • Neritatien with bases such as metal or ammonium salts.
  • alkali metal salts for example sodium or potassium salts
  • alkaline earth metal salts for example magnesium or calcium salts
  • ammonium salts which are derived from ammonia or organic amines, such as, for example, ethylamine, di- or triethylamine, ethyldiisopropylamine, monoethanolamine, di- or Triethanolamine, dicyclohexylamine, dimethylaminoethanol, dibenzylamine, N-methylmorpholine, dihydroabietylamine, 1-ephenamine, methylpiperidine, arginine, lysine, ethylenediamine or 2-phenylethylamine.
  • inventive compounds can also be in the form of their solvates, in particular in the form of their hydrates.
  • A represents a bond or a -CH 2 - or -CH 2 CH 2 - group
  • X represents O, S or CH 2
  • R 1 , R 2 and R 3 are identical or different and independently of one another represent hydrogen, (dC 6 ) -alkyl, (dC 6 ) -alkoxy, hydroxy, halogen, trifluoromethyl, trifluoromethoxy, nitro or cyano,
  • R 4 represents hydrogen or (dC) -alkyl
  • R and R are hydrogen or together with the carbon atom to which they are attached form a carbonyl group
  • R 7 is hydrogen, (dC 6 ) alkyl, phenyl or benzyl, in which the above
  • Aromatics for their part can be substituted one to three times in the same or different manner by (C 1 -C 6 ) -alkyl, (dC 6 ) -alkoxy, hydroxy or halogen,
  • R 8 is hydrogen, (C 6 -do) -aryl or for (dC 4 ) -alkyl, which in turn is optionally by (C 6 -do) -aryl or 5- to 6-membered heteroaryl with up to three heteroatoms from the series N, O and / or S is substituted, with all the ring systems mentioned being in turn one to three times the same or different by halogen, hydroxy, (dC 6 ) -alkyl, (dC 6 ) -alkoxy, trifluoromethyl, trifluoromethoxy, cyano, Nitro or amino can be substituted,
  • R 9 and R 10 are the same or different and independently of one another represent hydrogen, (dC 6 ) -alkyl, (dC 6 ) -alkoxy, trifluoromethyl, trifluoromethoxy or halogen,
  • R and R are identical or different and independently of one another represent hydrogen or (dC 6 ) -alkyl or together with the carbon atom to which they are attached form a (C 4 -C 7 ) -cycloalkyl ring,
  • R 13 represents hydrogen or a hydrolyzable group which can be broken down into the corresponding carboxylic acid
  • A represents a -CH - or -CH 2 CH 2 group
  • X represents O, S or CH 2 ,
  • R 1 , R 2 and R 3 are the same or different and independently of one another
  • R 4 represents hydrogen or methyl
  • R 5 and R 6 are hydrogen or together with the carbon atom to which they are attached form a carbonyl group
  • R 7 represents hydrogen, (dC 4 ) alkyl or benzyl
  • R 8 represents hydrogen, phenyl, benzyl or 5-membered heteroarylmethyl with up to two heteroatoms from the series ⁇ , O and / or S, the aromatic ring systems mentioned being in turn each one to three times the same or different by chlorine, fluorine, bromine , Hydroxy, (dC 4 ) -alkyl, (dC 4 ) -alkoxy, trifluoromethyl or amino can be substituted, R 9 and R 10 are the same or different and independently of one another represent hydrogen, (dC 3 ) -alkyl, (dC 3 ) -alkoxy, trifluoromethyl, fluorine or chlorine,
  • R 11 and R 12 are the same or different and are independent of one another
  • R 13 represents hydrogen or a hydrolyzable group which can be broken down into the corresponding carboxylic acid
  • A represents a -CH 2 - or -CH 2 CH 2 - group
  • X represents O, S or CH 2 ,
  • R 1 represents hydrogen, methyl or methoxy
  • R and R are identical or different and are independently methyl, trifluoromethyl, methoxy, trifluoromethoxy, chlorine or fluorine,
  • R 4 represents hydrogen, R 5 and R 6 together with the carbon atom to which they are attached form a carbonyl group
  • R 7 represents methyl, ethyl, n-propyl or in particular hydrogen
  • R 8 represents phenyl, furanylmethyl or thienylmethyl, where the said
  • Ring systems in turn can be substituted one or two times in the same or different way by methyl or ethyl,
  • R 9 and R 10 are the same or different and represent hydrogen or methyl and in particular hydrogen
  • R u and R 12 are the same or different and represent hydrogen or methyl and in particular methyl,
  • R 13 represents a hydrolyzable group which can be broken down into the corresponding carboxylic acid, or in particular represents hydrogen,
  • radical definitions specified in detail in the respective combinations or preferred combinations of radicals are also replaced by radical definitions of other combinations, irrespective of the respectively specified combinations of the radicals.
  • R represents hydrogen.
  • R 1 represents hydrogen, methyl or methoxy
  • R and R are the same or different and independently of one another represent methyl, isopropyl, tert-butyl, cyclohexyl, trifluoromethyl, methoxy, trifluoromethoxy, chlorine or fluorine.
  • R represents phenyl, furanylmethyl, thienylmethyl or oxazolylmethyl, where the ring systems mentioned may in turn be substituted one to two times by methyl, or represents 2-methoxyethyl.
  • X represents O or S
  • R 1 represents hydrogen, methyl or methoxy
  • R 2 and R 3 are the same or different and are independently methyl, isopropyl, tert-butyl, cyclohexyl, trifluoromethyl, methoxy, trifluoromethoxy, chlorine or fluorine,
  • R represents phenyl, furanylmethyl, thienylmethyl or oxazolylmethyl, where the ring systems mentioned may in turn be substituted one to two times by methyl, or represents 2-methoxyethyl.
  • T represents benzyl, (dC 6 ) -alkyl or a polymeric carrier suitable for solid-phase synthesis
  • R 1 , R 2 and R 3 have the meaning given above,
  • R 1 , R 2 , R 3 and R 7 have the meaning given above
  • Q represents a suitable leaving group, such as halogen, mesylate or tosylate, preferably bromine or iodine,
  • R 13 has the meaning given above
  • Z represents a suitable leaving group, such as, for example, halogen, mesylate or tosylate, or a hydroxyl group,
  • the process according to the invention is generally carried out at normal pressure. However, it is also possible to carry out the process under overpressure or under underpressure (e.g. in a range from 0.5 to 5 bar).
  • Customary organic solvents which do not change under the reaction conditions are suitable as solvents for the process.
  • ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, or hydrocarbons such as
  • Benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, or halogenated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, dichloroethylene, trichlorethylene or chlorobenzene, or ethyl acetate, pyridine, dimethyl sulfoxide, dimethylformamide, N, N'h'-dimethyl, N-methylpyrrolidone (NMP), acetonitrile, acetone or nitromethane. It is also possible to use mixtures of the solvents mentioned.
  • Preferred solvents for process step (II) + (III) - »(Ia) are dichloromethane and dimethylformamide. Dimethylformamide is preferred for process step (IN) + (N) - »(Ia).
  • the process step (II) + (III) - (Ia) according to the invention is generally carried out in a temperature range from 0 ° C. to + 100 ° C., preferably from 0 ° C. to + 40 ° C.
  • the process step (IV) + (V) - »(Ia) is generally carried out in a temperature range from 0 ° C. to + 120 ° C., preferably from + 50 ° C. to + 100 ° C.
  • Auxiliaries for the amide formation in process step (II) + (III) - (Ia) are preferably conventional condensing agents, such as carbodiimides, e.g. ⁇ , ⁇ '-Diethyl, N, N'-dipropyl, N, N'-diisopropyl, N, N'-dicyclohexylcarbodiimide (DCC), N- (3-dimethylaminoisopropyl) -N'-ethylcarbodiimide hydrochloride (EDC ), or
  • Carbonyl compounds such as carbonyldiimidazole, or 1,2-oxazolium compounds such as 2-ethyl-5-phenyl-l, 2-oxazolium-3-sulfate or 2-tert-butyl-5-methyl-isoxazolium perchlorate, or acylamino compounds such as 2 -Ethoxy-l-ethoxycarbonyl-l, 2-dihydroquinoline, or propanephosphonic anhydride, or isobutylchloroformate, or bis- (2-oxo-3-oxazolidinyl) phosphoryl chloride or benzotriazolyloxytris (dimethylamino) phosphonium hexafluorophosphate, or O- (benz l-yl) - N ⁇ N ⁇ N'-tetramethyluronium hexafluorophosphate (HBTU), 2- (2-oxo-l - (2H) - pyridyl) -lJ,
  • N-hydroxysuccinimide and as bases alkali carbonates, e.g. Sodium or potassium carbonate or bicarbonate, or organic bases such as trialkylamines, e.g. Triethylamine, N-methylmorpholine, N-methylpiperidine or diisopropylethylamine.
  • alkali carbonates e.g. Sodium or potassium carbonate or bicarbonate
  • organic bases such as trialkylamines, e.g. Triethylamine, N-methylmorpholine, N-methylpiperidine or diisopropylethylamine.
  • Suitable bases for the reaction (IV) + (V) - »(Ia) are the customary inorganic bases, such as alkali metal hydroxides, such as, for example, lithium, sodium or potassium hydroxide, alkali metal or alkaline earth metal carbonates, such as sodium, potassium, calcium or Cesium carbonate or sodium or potassium hydrogen carbonate, or organic bases, such as alkali metal hydroxides, such as, for example, lithium, sodium or potassium hydroxide, alkali metal or alkaline earth metal carbonates, such as sodium, potassium, calcium or Cesium carbonate or sodium or potassium hydrogen carbonate, or organic
  • Bases such as trialkylamines, e.g. Triethylamine, N-methylmorpholine, N-methylpiperidine or diisopropylethylamine.
  • Sodium bicarbonate is preferred.
  • Treated bases the salts formed initially being converted into the free carboxylic acids by treatment with acid.
  • the hydrolysis is preferably carried out with acids.
  • Suitable solvents for the hydrolysis of the carboxylic acid esters are water or the organic solvents customary for ester cleavage. These preferably include alcohols such as methanol, ethanol, propanol, isopropanol or butanol, or ethers such as tetrahydrofuran or dioxane, dimethylformamide, dichloromethane or dimethyl sulfoxide. It is also possible to use mixtures of the solvents mentioned. Water / tetrahydrofuran and, in the case of reaction with trifluoroacetic acid, dichloromethane and, in the case of hydrogen chloride, tetrahydrofuran, diethyl ether, dioxane or water are preferred.
  • the usual inorganic bases are suitable as bases for the hydrolysis. These preferably include alkali metal hydroxides or alkaline earth metal hydroxides such as, for example
  • Sodium hydroxide or lithium hydroxide are particularly preferably used.
  • Suitable acids are generally trifluoroacetic acid, sulfuric acid,
  • Hydrogen chloride, hydrogen bromide and acetic acid or mixtures thereof optionally with the addition of water.
  • Hydrogen chloride or trifluoroacetic acid are preferred in the case of the tert-butyl ester and hydrochloric acid in the case of the methyl ester.
  • the base or the acid is generally used in an amount of 1 to 100 mol, preferably 1.5 to 40 mol, based on 1 mol of the ester.
  • the hydrolysis is generally in a temperature range from 0 ° C to
  • R .14 [a-1] has the meaning of R given above
  • [a-2] represents a group of the formula wherein
  • R 7 has the meaning given above
  • R 15 represents (CC 4 ) alkyl or trimethylsilyl
  • Y represents a suitable leaving group, such as halogen, mesylate or tosylate, preferably bromine or iodine, to compounds of the general formula (XI)
  • R 17 represents hydrogen, (C 6 -C 10 ) aryl, 5- to 6-membered heteroaryl with up to three heteroatoms from the series N, O and / or S or (dC 3 ) alkyl, which in turn is represented by Hydroxy, trifluoromethoxy, (dC 4 ) alkoxy or
  • Phenoxy which in turn are optionally mono- to disubstituted by trifluoromethyl, or substituted by (C 6 -C 10 ) aryl or 5- to 6-membered heteroaryl with up to three heteroatoms from the series N, O and / or S. can, with all of the aryl and heteroaryl rings mentioned being in turn one to three times, the same or different, by
  • Halogen, hydroxy, (dC 6 ) -alkyl, (dC 6 ) -alkoxy, trifluoromethyl, trifluoromethoxy, cyano, nitro or amino can be substituted,
  • R 7 , R 15 and Y have the meaning given above,
  • the entire ner driving can also be carried out as a solid phase synthesis.
  • Carboxylic acid esters are attached to a suitable carrier resin, the further reactions are carried out on a solid phase and the target compound is finally removed from the resin. columns. Solid phase synthesis as well as the connection and the separation from the resin are common standard techniques. As an example from the extensive literature, reference is made to the publication "Linkers for Solid Phase Organic Synthesis", Ian W. James, Tetrahedron 55, 4855-4946 (1999).
  • reaction (VII) + (VIII) - (IX) or (XII) + (XIII) -> (XIV) takes place in the solvents which are customary for reductive amination and are inert under the reaction conditions, if appropriate in the presence of an acid.
  • solvents include, for example, water, dimethylformamide, tetrahydrofuran, dichloromethane, dichloroethane or alcohols such as methanol, ethanol, propanol, or isopropanol
  • butanol it is also possible to use mixtures of the solvents mentioned. Methanol and ethanol are preferred with the addition of acetic acid.
  • Preferred reducing agents are sodium cyanoborohydride, sodium triacetoxyborohydride and tetrabutylammonium borohydride.
  • reaction (VII) + (VIII) ⁇ (IX) or (XII) + (XIII) ⁇ (XIV) generally takes place in a temperature range from 0 ° C to + 40 ° C.
  • reaction (IX) + (X) - (XI) or (XIV) + (XV) - »(XVI) is carried out in the customary solvents which are inert under the reaction conditions.
  • Dimethylformamide, tetrahydrofuran and dioxane are preferred.
  • the usual inorganic or organic bases are suitable as bases for the reaction (IX) + (X) - (XI) or (XIV) + (XV) ⁇ (XVI). Triethylamine is preferred.
  • the reaction (IX) + (X) ⁇ (XI) or (XIV) + (XV) ⁇ (XVI) generally takes place in a temperature range from 0 ° C to + 100 ° C.
  • reaction (XI) - (II) or (XVI) - »(II) takes place in the solvents which are customary for ester cleavage and are inert under the reaction conditions.
  • these are preferably tetrahydrofuran, dioxane and alcohols such as methanol and ethanol, each in a mixture with water.
  • dioxane or tetrahydrofuran is preferably used.
  • the usual inorganic bases are suitable as the base for the reaction (XI) - »(II) or (XVI) ⁇ (II).
  • Lithium, sodium and potassium hydroxide are preferred.
  • silylester cleavage tetrabutylammonium fluoride is preferably used.
  • reaction (XI) - »(II) or (XVI) -» (II) generally takes place in a temperature range from 0 ° C to + 100 ° C.
  • the compounds of the general formula (IV) correspond to the compounds of the general formula (IX) or (XIV) and can be prepared as described above.
  • inventive compounds of the formula (I) have a surprising and valuable spectrum of pharmacological activity and can therefore be used as versatile medicaments.
  • they are suitable for the treatment of coronary artery disease, for the prevention of myocardial infarction and for the treatment of
  • they can be used to treat obesity, diabetes, to treat metabolic syndrome (glucose intolerance, hyperinsulinemia, and dyslipidemia
  • the effectiveness of the Neritatien invention can e.g. Check in vitro using the transactivation assay described in the example section.
  • the effectiveness of the Neritatien invention in vivo can be e.g. check by the examinations described in the example section.
  • all customary application forms come into consideration, i.e. i.e. orally, parenterally, inhalatively, nasally, sub-lingually, rectally or externally, e.g. transdermally, particularly preferably orally or parenterally.
  • parenteral administration intravenous, intramuscular, subcutaneous administration should be mentioned in particular, e.g. as a subcutaneous depot.
  • Oral application is very particularly preferred.
  • the active ingredients can be administered alone or in the form of preparations.
  • suitable preparations include Tablets, capsules, pellets, coated tablets, pills, granules, solid and liquid aerosols, syrups, emulsions, suspensions and solutions.
  • the active ingredient can be present in a concentration of 0.1 to 100% by weight, in particular 0.5 to 90% by weight, preferably 5 to 80% by weight.
  • the concentration of the active ingredient should be 0.5-90% by weight, ie the active ingredient should be present in amounts which are sufficient to achieve the dosage range indicated.
  • the active ingredients can be converted into the customary preparations in a manner known per se. This is done using inert, non-toxic, pharmaceutically suitable carriers, auxiliaries, solvents, vehicles, emulsifiers and or dispersants.
  • auxiliary substances are: water, non-toxic organic solvents such as e.g. Paraffins, vegetable oils (e.g. sesame oil), alcohols (e.g. ethanol, glycerin), glycols (e.g. polyethylene glycol), solid carriers such as natural or synthetic stone powder (e.g. talc or silicates), sugar (e.g.
  • non-toxic organic solvents such as e.g. Paraffins, vegetable oils (e.g. sesame oil), alcohols (e.g. ethanol, glycerin), glycols (e.g. polyethylene glycol), solid carriers such as natural or synthetic stone powder (e.g. talc or silicates), sugar (e.g.
  • Milk sugar emulsifiers
  • dispersants e.g. polyvinylpyrrolidone
  • lubricants e.g. magnesium sulfate
  • tablets can of course also contain additives such as sodium citrate together with additives such as starch, gelatin and the like.
  • additives such as sodium citrate together with additives such as starch, gelatin and the like.
  • Aqueous preparations for oral administration can also be mixed with flavor enhancers or colorants.
  • dosages of 0.001 to 5 mg / kg, preferably 0.005 to 3 mg / kg of body weight are preferably administered per 24 hours.
  • Lithium-sol slowly added dropwise. When the addition is complete, it will Mixture stirred for 1 h at -78 ° C, then a solution of 15.76 g (63.04 mmol) of 4-bromobenzyl bromide in 10 ml of tetrahydrofuran is added and the mixture is stirred for 1 h at -78 ° C. The reaction is then warmed to room temperature, poured into 100 ml of 1N hydrochloric acid, the phases are separated and the aqueous phase is extracted 3 times with diethyl ether. The combined organic phases are washed with NaHCO 3 solution. washed, over
  • a solution of 24.4 g (200 mmol) of 4-hydroxybenzaldehyde in 100 ml of dimethylformamide is mixed with 97.75 g (300 mmol) of cesium carbonate and stirred at 90 ° C. for 1 h.
  • a solution of 66.93 g (300 mmol) of tert-butyl 2-bromo-isobutyrate in 100 ml of dimethylformamide is then added dropwise and the mixture is stirred at 90 ° C. overnight. After distilling off the dimethylformamide in vacuo, the residue is taken up in ethyl acetate, 2x with water, 2x with 1N sodium hydroxide solution and lx with sat. NaCl solution.
  • Example 1-6 Analogously to the procedure of Example 1-9, 198 mg (0.583 mmol) of tert-butyl 3- [4- (anilinomethyl) phenyl] -2,2-dimethylpropionate (Example 1-6), 108 mg (0.292 mmol) of Tefra -n-butylammonium iodide, twice with 89 mg (0.875 mmol) triethylamine and three times with 146 mg (0.875 mmol)
  • Example 1-7 Analogously to the procedure of Example 1-9, 181 mg (0.512 mmol) of tert-butyl-2,2-dimethyl-3- (4 - ⁇ [(4-methylphenyl) amino] methyl ⁇ phenyl) propionate (Example 1-7 ), 95 mg (0.256 mmol) tetra-n-butylammonium iodide, twice with 78 mg (0.768 mmol) triethylamine and three times with 128 mg (0.768 mmol) ethyl bromoacetate in 2 ml tetrahydrofuran and 2 ml dimethylformamide
  • Example 1-12 Analogously to the procedure of Example 1-12, 175 mg (0.411 mmol) of tert-butyl-3- (4 - ⁇ [(2-ethoxy-2-oxoethyl) (2-phenyl) amino] methyl ⁇ phenyl) -2, 2-dimethyl-propionate (Example 1-10) and 1.23 ml (1.23 mmol) 1 ⁇ sodium hydroxide solution in 3 ml ethanol 162 mg (99%) of the N- [4- (3-tert-butoxy-2, 2-dimethyl-3-oxopropyl) benzyl] -N-phenylglycins obtained.
  • Example 1-12 Analogously to the procedure of Example 1-12, 750 mg (2.05 mmol) of methyl 2- ⁇ [4- (2-tert-butoxy-1,1, dimethyl-2-oxoethoxy) benzyl] amino ⁇ butyrate (Example 1-8) and 6.20 ml (6.20 mmol) of 1 N sodium hydroxide solution in 6 ml of ethanol 640 mg (89%) of the 2 - ⁇ [4- (2-tert-butoxy-1 J -dimethyl-2-oxoethoxy ) benzyl] amino ⁇ butyric acid.
  • 2,4-dimethylaniline in 8 ml of dimethylformamide are 88 mg (0.648 mmol) of 1-hydroxy-1H-benzotriazole, 124 mg (0.648 mmol) of 1-ethyl-3- (3-dimethylamino) propylcarbodiimide hydrochloride at 0 ° C, 151 mg (1.494 mmol) of N-methylmorpholine and 3 mg (0.025 mmol) of 4-dimethylaminopyridine were added and the solution was stirred at this temperature for 1 h. The mixture is then stirred at room temperature for 9 h and then 10 ml of water are added.
  • aqueous phase is extracted twice with ethyl acetate, the combined organic phases are saturated with 1 ⁇ hydrochloric acid. ⁇ aHCO 3 solution. and sat. NaCl solution. washed, dried over sodium sulfate and freed from solvent in vacuo.
  • Example 1-13 65 mg (0.164 mmol) of N- [4- (3-tert-butoxy-2,2-dimethyl-3-oxopropyl) benzyl] -N-phenylglycine (Example 1-13), 30 mg (0.245 mmol) 2,4-dimethylaniline, 29 mg (0.213 mmol) 1-hydroxy-lH-benzotriazole, 41 mg (0.213 mmol) l-ethyl-3- (3-dimethylamino) propylcarbodiimide hydrochloride, 50 mg ( 0.491 mmol) N-methylmorpholine and 0.2 mg (0.002 mmol) 4-dimethylaminopyridine in 2 ml dimethylformamide to 65 mg (79%) of tert-butyl-3- (4 - ⁇ [N- (2- (2 , 4-dimethylphenyl) amino-2-oxo) ethyl-N-phenylamino] methyl ⁇
  • Butoxy-2,2-dimethyl-3-oxopropyl) benzyl] -N-phenylglycine (Example 1-13), 37 mg (0.245 mmol) 4-methoxy-2,5-dimethylaniline, 29 mg (0.213 mmol) 1-hydroxy -lH-benzotriazole, 41 mg (0.213 mmol) l-ethyl-3- (3-dimethylamino) propylcarbodiimide hydrochloride, 50 mg (0.491 mmol) N-methylmorpholine and 0.2 mg (0.002 mmol) 4-dimethylaminopyridine in 2 ml Dimethylforamide to 78 mg (90%) of tert-butyl-3-
  • Example I- 14 50 mg (0.121 mmol) of N- [4- (3-tert-butoxy-2,2-dimethyl-3-oxopropyl) benzyl] -N- (4-methylphenyl) glycine (Example I- 14), 22 mg (0.182 mmol) 2,4-dimethylaniline, 21 mg (0.158 mmol) 1-hydroxy-lH-benzotriazole, 30 mg (0.158 mmol) l-ethyl-3- (3-dimethylamino) propylcarbodiimide- Hydrochloride, 37 mg (0.364 mmol) of N-methylmorpholine and 0.1 mg (0.001 mmol) of 4-dimethylaminopyridine in 2 ml of dimethylformamide to 40 mg (64%) of the tert-butyl-3- (4 - ⁇ [N- (2 - (2,4-dimethylphenyl) amino-2-oxo) ethyl-
  • Example 1-14 Analogously to the procedure of Example 1-1, 50 mg (0.121 mmol) of N- [4- (3-tert-butoxy-2,2-dimethyl-3-oxopropyl) benzyl] -N- (4-methylphenyl) glycine (Example 1-14), 28 mg (0.182 mmol) 4-methoxy-2,5-dimethylaniline, 21 mg (0.158 mmol) 1-hydroxy-lH-benzotriazole, 30 mg (0.158 mmol) l-ethyl-3- (3- dimethylamino) propyl carbodiimide hydrochloride, 37 mg (0.364 mmol) N-methylmorpholine and 0.1 mg (0.001 mmol) 4-dimethylaminopyridine in 2 ml dimethylformamide to 58 mg (88%) of tert-butyl-3- (4- ⁇ [N- (2- (4-methoxy-2,5-dimethylphenyl) amino-2-oxo)
  • Example 1-3 48 mg (0.096 mmol) of tert-butyl-3- (4- ⁇ [N- (2- (2,4-dimethylphenyl) amino-2-oxo) ethyl-N-phenylamino] methyl ⁇ phenyl) -2,2-dimethylpropionate (Example 1-3) with 1 ml trifluoroacetic acid in 2 ml dichloromethane to 36 mg (85%) of the 3- (4 - ⁇ [N- (2- (2,4-dimethylphenyl ) amino-2-oxo) ethyl-N-phenylamino] methyl ⁇ phenyl) -2,2-dimethylpropionic acid.
  • Example 1-4 tert-butyl-3- (4- ⁇ [N- (2- (4-methoxy-2,5-dimethylphenyl) amino-2-oxo) ethyl N-phenylamino] methyl ⁇ - phenyl) -2,2-dimethylpropionate (Example 1-4) with 1 ml trifluoroacetic acid in 2 ml dichloromethane to 46 mg (85%) of the 3- (4 - ⁇ [N- (2- ( 4-methoxy-2,5-dimethyl ⁇ henyl) - amino-2-oxo) ethyl-N-phenylamino] methyl ⁇ phenyl) -2,2-dimethylpropionic acid.
  • Example 1-9 Analogously to the procedure of Example 1-9, 23 mg (0.049 mmol) of tert-butyl-3- (4- ⁇ [N- (2- (2,4-dimethylphenyl) amino-2-oxo) ethyl-N- (4th -methylphenyl) amino] methyl ⁇ - phenyl) -2,2-dimethylpropionate (Example 1-5) with 1 ml trifluoroacetic acid in 2 ml dichloromethane to 20 mg (91%) of the 3- (4 - ⁇ [N- ( 2- (2,4-Dimethylphenyl) amino-2-oxo) - ethyl-N- (4-methylphenyl) amino] methyl ⁇ phenyl) -2,2-dimethylpropionic acid.
  • Example 1-6 40 mg (0.073 mmol) of tert-butyl-3- (4- ⁇ [N- (2- (4-methoxy-2,5-dimethylphenyl) amino-2-oxo) ethyl N- (4-methylphenyl) - amino] methyl ⁇ phenyl) -2,2-dimethylpropionate (Example 1-6) with 1 ml trifluoroacetic acid in 2 ml dichloromethane to 33 mg (93%) of the 3- (4 - ⁇ [N - (2- (4-Methoxy-2,5-dimethylphenyl) amino-2-oxo) ethyl-N- (4-methylphenyl) amino] methyl ⁇ phenyl) -2,2-dimethylpropionic acid.
  • Example 1-9 Analogously to the instructions in Example 1-9, 170 mg (0.374 mmol) of tert-butyl-2- (4 - ⁇ [(l - ⁇ [(2,4-dimethylphenyl) amino] carbonyl ⁇ propyl) amino] methyl ⁇ phenoxy) -2-methylpropionate (Example 1-7) with 0.72 ml (9.35 mmol) trifluoroacetic acid in 3 ml dichloromethane to 113 mg (72%) of the 2- (4 - ⁇ [(l - ⁇ [(2.4 -Dimethyl ⁇ henyl) amino] - carbonyl ⁇ propyl) amino] methyl ⁇ phenoxy) -2-methylpropionic acid.
  • Example 1-9 Analogously to the procedure of Example 1-9, 115 mg (0.237 mmol) of tert-butyl-2- (4 - ⁇ [(1 - ⁇ [(4-methoxy-2,5-dimethylphenyl) amino] carbonyl ⁇ propyl) amino] -methyl ⁇ - phenoxy) -2-methylpropionate (Example 1-8) with 0.46 ml (5.93 mmol) trifluoroacetic acid in 3 ml dichloromethane to 100 mg (93%) of the 2- (4 - ⁇ [( l - ⁇ [(4-methoxy-2,5-dimethylphenyl) amino] carbonyl ⁇ propyl) amino] methyl ⁇ phenoxy) -2-methyl-propionic acid.
  • 1,1-dimethylethyl ester are dissolved in 270 ml of tetrahydrofuran and 2.27 g of triethylamine and 3.74 g of ethyl bromoacetate and 14.85 g of tetra-n-butylammonium iodide are added. The mixture is stirred at 90 ° C. for 48 h, cooled and water and ethyl acetate are added. The org. Phase is separated off and twice with sat. NaCl solution. washed. Drying (MgSO 4 ), concentration and chromatographic purification (cyclohexane / ethyl acetate 5 + 1) gives 6.4 g of a colorless oil!
  • Example II-9 2 - [[4 - [[(2-methoxyethyl) amino] methyl] phenyl] thio] -2-methyl-propanoic acid-1J-dimethylethyl ester
  • Example 11-12 2-Bromo-N- (2,4-dichlorophenyl) acetamide This compound was prepared analogously to Example 11-11 from 4.2 g of 2,4-dichloroaniline and 5.76 g of bromoacetyl bromide and 2.89 g of triethylamine in methylene chloride. 5.9 g (80.4%) of the title compound were obtained.
  • MS (EI pos.): M + 283.
  • N '- (3-Dimethylaminopropyl) -N-ethylcarbodiimide hydrochloride was added and dissolved in 5 ml of dichloromethane. The mixture is stirred at room temperature for 20 h and extracted with 1 N NaOH, 1 N HCl, water and sat. NaCl solution. The combined organic phases are dried (MgSO 4) and purified by chromatography (dichloromethane ethyl acetate 25 + 1). 210 mg of a viscous oil are obtained.
  • Example 2-6 2 - [[4 - [[[2 - [(2,4,6-trimethylphenyl) amino] -2-oxoethyl] (2-furanylmethyl) amino] - methyl] phenyl] thio] -2-methyl propanoic
  • Dioxane are added at room temperature to 31.60 g (281.48 mmol) of potassium t-butoxide and 52.70 (270.22 mmol) of t-butyl bromoacetate and heated to boiling overnight. After adding 1 liter of water, the mixture is extracted with diethyl ether, washed with 1N sodium hydroxide solution, water and saturated sodium chloride solution, dried over magnesium sulfate and the solvent is distilled off.
  • Reaction solution is mixed with saturated sodium bicarbonate solution and vinegar acid ethyl ester added. After drying the organic phase over magnesium sulfate and distilling off the solvent, the residue is purified by flash chromatography on silica gel (cyclohexane ⁇ cyclohexane / ethyl acetate 10: 1 ⁇ 2: 1) and by means of NP-HPLC (cyclohexane / ethyl acetate 10: 1). The target compound is obtained in a yield of 79%.
  • Example 111-16 with 0.23 g (1.88 mmol) of 2,4-dimethylaniline, 0.22 g (1.63 mmol) of 1-hydroxy-1H-benzotriazole, 0.31 g (1.63 mmol) of EDCxHCl , 0.38 g (3.75 mmol) of 4-methylmorpholine and 0.01 g (0.08 mmol) of 4-dimethylaminopyridine were stirred for 2 hours at 0 ° C. and overnight at room temperature. After adding water and extraction with ethyl acetate, the organic phases are washed with 1N hydrochloric acid, water, saturated sodium bicarbonate and saturated sodium chloride solution and then dried over magnesium sulfate.
  • Example 3-8 2- [4 - [[(2-methoxyethyl) [2 - [[4- (l-methylethyl) -2- (trifluoromethyl) phenyl] amino] -2-oxoethyl] amino] methyl] phenoxy] - 2-methyl-propionic acid
  • the reaction mixture is stirred for 2 hours at room temperature. The mixture is then evaporated in vacuo. The residue is dissolved in ethyl acetate added and washed with water, 20% sodium acetate solution, water and saturated sodium chloride solution. The organic phase is dried over magnesium sulfate and freed from the solvent in vacuo.
  • the product is purified by chromatography on silica gel (dichloromethane / methanol 30: 1). The residue is dissolved in dichloromethane with heating, IN hydrochloric acid in diethyl ether is added and n-heptane is added dropwise until the mixture becomes slightly cloudy. The product is filtered off, washed with diethyl ether and dried in vacuo at 40 ° C. 0.187 g (49% of theory) of the title compound are obtained.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
EP01974287A 2000-10-05 2001-09-24 Propionsäurederivate mit ppar-alpha aktivierenden eigenschaften Withdrawn EP1328508A2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE10049208 2000-10-05
DE10049208 2000-10-05
DE10124905 2001-05-22
DE10124905A DE10124905A1 (de) 2000-10-05 2001-05-22 Propionsäurederivate
PCT/EP2001/011005 WO2002028821A2 (de) 2000-10-05 2001-09-24 Propionsäurederivate mit ppar-alpha aktivierenden eigenschaften.

Publications (1)

Publication Number Publication Date
EP1328508A2 true EP1328508A2 (de) 2003-07-23

Family

ID=26007267

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01974287A Withdrawn EP1328508A2 (de) 2000-10-05 2001-09-24 Propionsäurederivate mit ppar-alpha aktivierenden eigenschaften

Country Status (22)

Country Link
EP (1) EP1328508A2 (pl)
JP (1) JP2004510757A (pl)
CN (1) CN1479716A (pl)
AU (1) AU2001293838A1 (pl)
BG (1) BG107684A (pl)
BR (1) BR0114437A (pl)
CA (1) CA2424540A1 (pl)
CZ (1) CZ2003964A3 (pl)
EE (1) EE200300140A (pl)
HN (1) HN2001000223A (pl)
HR (1) HRP20030346A2 (pl)
HU (1) HUP0302306A3 (pl)
IL (1) IL155125A0 (pl)
MA (1) MA25917A1 (pl)
MX (1) MXPA03002901A (pl)
NO (1) NO20031517L (pl)
NZ (1) NZ525119A (pl)
PL (1) PL361162A1 (pl)
RU (1) RU2003112968A (pl)
SK (1) SK4132003A3 (pl)
UY (1) UY26951A1 (pl)
WO (1) WO2002028821A2 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10151390A1 (de) * 2001-10-18 2003-05-08 Bayer Ag Essigsäurederivate
GB0214254D0 (en) 2002-06-20 2002-07-31 Glaxo Group Ltd Chemical compounds
KR20050055773A (ko) * 2002-10-21 2005-06-13 얀센 파마슈티카 엔.브이. 치환된 테트라린 및 인단
AU2003279996B2 (en) * 2002-10-21 2009-07-09 Janssen Pharmaceutica, N.V. Substituted tetralins and indanes and their use
CA2503405A1 (en) * 2002-10-21 2004-05-06 Janssen Pharmaceutica, N.V. Treating syndrome x with substituted tetralins and indanes
AU2003296402A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Thiophene derivative ppar modulators
KR20110140139A (ko) 2003-08-29 2011-12-30 오노 야꾸힝 고교 가부시키가이샤 Ｓ１ｐ 수용체 결합능을 갖는 화합물 및 그 의약 용도
AR048931A1 (es) 2004-04-21 2006-06-14 Janssen Pharmaceutica Nv Proceso para la preparacion de derivados de tetralina sustituida e indano sustituido y preparacion de intermediarios de sintesis
CN100344618C (zh) * 2004-05-24 2007-10-24 北京摩力克科技有限公司 作为hPPARα和hPPARγ激动剂的N－芳丙烯酰基取代的酪氨酸衍生物
KR100699928B1 (ko) * 2004-10-05 2007-03-26 재단법인서울대학교산학협력재단 퍼록시솜 증식자 활성화 수용체 알파 리간드를 제조하기위한 중간체의 제조방법
BRPI0519012A2 (pt) 2004-12-13 2008-12-23 Ono Pharmaceutical Co derivado do Ácido aminocarboxÍlico e seu uso medicinal
CN101054372B (zh) * 2006-04-11 2010-10-13 中国科学院上海药物研究所 嘧啶取代苯丙酸衍生化合物、其制法和在治疗多囊肾疾病中的用途
TW201022221A (en) 2008-12-01 2010-06-16 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivatives containing thiazole ring and pharmaceutical use thereof
JP5436941B2 (ja) * 2009-06-03 2014-03-05 あすか製薬株式会社 ラクタム化合物又はその塩及びｐｐａｒ活性化剤
UY34200A (es) 2011-07-21 2013-02-28 Bayer Ip Gmbh 3-(fluorovinil)pirazoles y su uso
EP3230304B1 (en) * 2014-12-11 2020-01-01 Centrient Pharmaceuticals Netherlands B.V. Method for acylating a cyclic peptide

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2320387A1 (de) * 1973-04-21 1974-10-31 Boehringer Mannheim Gmbh Phenoxyalkylcarbonsaeurederivate und verfahren zur herstellung derselben
GB9822473D0 (en) * 1998-10-16 1998-12-09 Glaxo Group Ltd Chemical compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0228821A2 *

Also Published As

Publication number Publication date
AU2001293838A1 (en) 2002-04-15
HN2001000223A (es) 2001-10-25
SK4132003A3 (en) 2004-02-03
RU2003112968A (ru) 2004-09-20
MXPA03002901A (es) 2003-10-15
CZ2003964A3 (cs) 2003-08-13
CN1479716A (zh) 2004-03-03
BR0114437A (pt) 2003-07-01
HUP0302306A3 (en) 2005-02-28
IL155125A0 (en) 2003-10-31
EE200300140A (et) 2003-08-15
HRP20030346A2 (en) 2005-04-30
NO20031517D0 (no) 2003-04-03
BG107684A (bg) 2003-10-31
PL361162A1 (pl) 2004-09-20
NZ525119A (en) 2005-04-29
JP2004510757A (ja) 2004-04-08
WO2002028821A2 (de) 2002-04-11
NO20031517L (no) 2003-05-28
UY26951A1 (es) 2002-06-20
HUP0302306A2 (hu) 2003-10-28
MA25917A1 (fr) 2003-10-01
WO2002028821A3 (de) 2002-08-15
CA2424540A1 (en) 2003-04-02

Similar Documents

Publication Publication Date Title
EP1328508A2 (de) Propionsäurederivate mit ppar-alpha aktivierenden eigenschaften
DE60014588T2 (de) Thioamidderivate
US7553867B2 (en) Furan or thiophene derivative and medicinal use thereof
DE69728375T2 (de) Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen
DE69432341T2 (de) Catecholaminersatz-Verbindungen, nützlich als beta 3 Agonisten
RU2529484C2 (ru) Ациламино-замещенные производные конденсированных циклопентанкарбоновых кислот и их применение в качестве фармацевтических средств
US6548538B2 (en) Propionic acid derivatives
WO2012076466A2 (de) Substituierte 1-benzylcycloalkylcarbonsäuren und ihre verwendung
CN109071459B (zh) Ppar激动剂、化合物、药物组合物以及它们的使用方法
CN104892542A (zh) 抗炎症的2-羰基噻唑和2-羰基恶唑
US6828446B2 (en) Aromatic thioether liver X-receptor modulators
DE3881842T2 (de) Substituierte alkylamin-derivate.
WO2007141423A1 (fr) Derives activateurs de ppars, procede de preparation et application en therapeutique.
AU2003241579B9 (en) Amide linker peroxisome proliferator activated receptor modulators
DE69402004T2 (de) Beta-mercapto-propanamidderivate verwendbar zur Behandlung kardiovaskularer Krankheiten oder Erkrankungen
DE10124905A1 (de) Propionsäurederivate
CA2126917C (fr) Nouveaux n-phenyl 2-cyano 3-hydroxy propenamides, leurs formes tautomeres et leurs sels, leur procede de preparation, l'application a titre de medicaments de ces nouveaux produitset les compositions les renfermant
Sparatore et al. [4‐(2H‐1, 2, 3‐Benzotriazol‐2‐yl) phenoxy] alkanoic Acids as Agonists of Peroxisome Proliferator‐Activated Receptors (PPARs)
JP2005035966A (ja) フランまたはチオフェン誘導体およびその医薬用途
ES2352071T3 (es) Derivados de tirosina sustituidos con n-fenilacroloilo como agonostas de hppar alfa y de hppar gama.
KR20040088508A (ko) 신규 프로피온산 유도체
HK1063460A (en) Propionic acid derivatives with pparalpha activating properties

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030506

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER HEALTHCARE AG

17Q First examination report despatched

Effective date: 20050408

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050519